Intraocular Implants for the Treatment of Autoimmune Uveitis

Journal of Functional Biomaterials

Darren J. Lee¹ 

[1] Department of Ophthalmology/Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, 608 Stanton L. Young Blvd, DMEI PA404, Oklahoma City, OK 73104, USA; E-Mail

关键词: uveitis;    non-infectious uveitis;    intraocular implant;    uveitis treatment;    ocular drug delivery device;   

DOI  :  10.3390/jfb6030650

来源: mdpi

【 摘 要 】

Uveitis is the third leading cause of blindness in developed countries. Currently, the most widely used treatment of non-infectious uveitis is corticosteroids. Posterior uveitis and macular edema can be treated with intraocular injection of corticosteroids, however, this is problematic in chronic cases because of the need for repeat injections. Another option is systemic immunosuppressive therapies that have their own undesirable side effects. These systemic therapies result in a widespread suppression of the entire immune system, leaving the patient susceptible to infection. Therefore, an effective localized treatment option is preferred. With the recent advances in bioengineering, biodegradable polymers that allow for a slow sustained-release of a medication. These advances have culminated in drug delivery implants that are food and drug administration (FDA) approved for the treatment of non-infectious uveitis. In this review, we discuss the types of ocular implants available and some of the polymers used, implants used for the treatment of non-infectious uveitis, and bioengineered alternatives that are on the horizon.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.